Drugs / ASC30
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06680440 | Aug 2024 → Apr 2025 | — | Ascletis Pharma Inc | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06679959 | Sep 2024 → Mar 2026 | — | Ascletis Pharma Inc | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07321678 | Jan → Aug 2026 overdue | type 2 diabetes mellitus | Ascletis Pharma Inc | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07002905 | Jul → Dec 2025 | — | Ascletis Pharma Inc | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-08-03 | Ascletis Pharmaceuticals Co., Ltd. | Regulatory 歌礼宣布其GLP-1口服小分子ASC30启动全球III期临床研究，并公布其同类首创口服小分子GLP-1/GIP/胰淀素固定剂量复方制剂的积极临床前数据 ascletis.com ↗
Hong Kong, August 3, 2026 – Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces once-daily oral small molecule GLP-1 (ASC30) has received Phase III clearance from the U.S. Food and Drug Administration (FDA). |
| 2025-12-08 | Ascletis Pharmaceuticals Co., Ltd. | Results 歌礼口服小分子GLP-1药物ASC30在肥胖或超重受试者中进行的美国13周II期研究显示经安慰剂校正后的体重下降高达7.7%，且胃肠道耐受性更佳 ascletis.com ↗ |
| 2025-11-05 | Ascletis Pharmaceuticals Co., Ltd. | Results 歌礼在2025年肥胖周（ObesityWeek®）报告ASC30口服片Ib期研究的完整分析、ASC30注射剂Ib期研究以及ASC31与ASC47联合用药临床前研究 ascletis.com ↗
Positive data from Phase Ib study of ASC30 oral tablet demonstrated up to 6.5% placebo-adjusted mean body weight reduction; safe and well tolerated with only mild-to-moderate gastrointestinal (GI) adverse events (AEs) across all multiple ascending dose (MAD) cohorts. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-08-03 | Ascletis Pharmaceuticals Co., Ltd. | 歌礼宣布其GLP-1口服小分子ASC30启动全球III期临床研究，并公布其同类首创口服小分子GLP-1/GIP/胰淀素固定剂量复方制剂的积极临床前数据 ascletis.com ↗ |
| 2025-12-08 | Ascletis Pharmaceuticals Co., Ltd. | 歌礼口服小分子GLP-1药物ASC30在肥胖或超重受试者中进行的美国13周II期研究显示经安慰剂校正后的体重下降高达7.7%，且胃肠道耐受性更佳 ascletis.com ↗ |
| 2025-11-05 | Ascletis Pharmaceuticals Co., Ltd. | 歌礼在2025年肥胖周（ObesityWeek®）报告ASC30口服片Ib期研究的完整分析、ASC30注射剂Ib期研究以及ASC31与ASC47联合用药临床前研究 ascletis.com ↗ |
| 2024-09-17 | Ascletis Pharmaceuticals Co., Ltd. | Ascletis Enters the Obesity Drug Space with Announcement of Two Ongoing U.S. Phase I Clinical Trials Utilizing Its Small Molecule GLP-1R Agonist ASC30 for Both Once-Monthly Subcutaneous Injection and Once-Daily Oral Tablet for the Treatment of Obesity ascletis.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASC30 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06680440 ↗ |
| Route | Subcutaneous | “ASC30 injection, for subcutaneous use” NCT06679959 ↗ |